Dong-A Socio, Alteogen & DMBio signs contract service agreement of macular degeneration treatment
Alteogen(CEO Soon-Jae Park), a company which are developing a biosimilar of macular degeneration treatment ‘Eylea,’ announced on the 28th that it signed a Eylea biosimilar manufacturing agreement with DMBio(Byung-Jo Min, Kawasaki Yoshikuni) and Dong-A Socio Holdings(CEO Jong-Hyun Han).
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.